Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
May 02, 2023 08:00 ET
|
Immutep Limited
Media Release Webinar to take place on Tuesday, May 9, 2023, at 11:30 AM ET SYDNEY, AUSTRALIA, May 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage...
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
May 01, 2023 08:00 ET
|
Immutep Limited
Media Release Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO® in metastatic...
Immutep Quarterly Activities Report
April 27, 2023 08:00 ET
|
Immutep Limited
Media Release Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast...
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
April 26, 2023 10:00 ET
|
Immutep Limited
Media Release Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA, April ...
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
April 26, 2023 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for...
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
April 17, 2023 09:00 ET
|
Immutep Limited
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosisFirst time efti will be studied in neoadjuvant, non-metastatic cancer settingNovel...
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
March 31, 2023 08:00 ET
|
Immutep Limited
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care...
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
March 30, 2023 08:00 ET
|
Immutep Limited
Media Release Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patientsExpansion based on safety and strong initial efficacy...
Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023
March 23, 2023 08:00 ET
|
Immutep Limited
Media Release 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting...
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
March 14, 2023 08:00 ET
|
Immutep Limited
Media Release Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and will help inform a BLA and MAAHR+/HER2-neg/low metastatic breast cancer (MBC) patient population has...